Sitravatinib, a spectrum-selective TKI targeting TAM receptors and VEGFR2, administered in combination with nivolumab induced durable response and robust survival outcomes for patients with non-small cell lung cancer who progressed after deriving benefit from treatment with a checkpoint inhibitor and/or platinum doublet chemotherapy.
Blood-based tumor mutational burden does not predict a benefit of first-line atezolizumab over chemotherapy in patients with non–small cell lung cancer.
The triplet combination of umbralisib, ublituximab, and pembrolizumab demonstrated durable responses with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation.
Andre H. Goy, MD, discusses the importance of refined decision making with precision medicine.
John L. Marshall, MD, discusses the importance of molecular profiling when utilizing precision medicine.
Benjamin P. Levy, MD, discusses potential strategies to overcome resistance to osimertinib in EGFR-mutant non–small cell lung cancer.
William G. Wierda, MD, PhD, discusses the fixed-duration cohort results of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.
Sikander Ailawadhi, MD, discusses the results of a first-in-human, early phase 1 study of lisaftoclax in patients with hematologic malignancies.
A genome-wide look into changes in three-dimensional chromatin organization between ibrutinib-resistant and parental chronic lymphocytic leukemia cells illustrated the involvement of PAK1 as an oncogenic driver in CLL.
Baseline tumor immunogenicity may be associated with higher pathologic complete response rates and favorable outcomes in hormone receptor-positive, HER2-positive early stage breast cancer when comparing de-escalated neoadjuvant ado-trastuzumab emtansine with or without endocrine therapy, vs trastuzumab plus endocrine therapy.
Zanubrutinib monotherapy showed a deepening of response in patients with relapsed/refractory chronic lymphocytic leukemia.
Adjuvant treatment with atezolizumab led to an improvement in disease-free survival and time to locoregional and distant relapse compared with best supportive care in prespecified subgroups of PD-L1–positive patients with stage II to IIIA NSCLC, according to exploratory findings from the phase 3 IMpower010 trial.
First-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.
TG-1701, a covalently bound BTK inhibitor, used as monotherapy or in combination with umbralisib and ublituximab, demonstrated promising activity and a manageable safety profile in patients with chronic lymphocytic leukemia.
Lisocabtagene maraleucel in combination with ibrutinib was associated with manageable safety for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to updated data from the phase 1 TRANSCEND-CLL-004 trial.
Clinical limit of detection may be a reasonable metric for evaluating cell-free DNA for multi-cancer early detection.
The anti-PD-1 antibody balstilimab in combination with the anti-CTLA-4 antibody zalifrelimab exhibited impressive response rates, duration of response, and overall survival in patients with previously treated recurrent/metastatic cervical cancer.
Jason J. Luke, MD, FACP, discusses the results of the phase 3 KEYNOTE-716 trial in high-risk stage II melanoma.
The frontline combination of nivolumab and chemotherapy upheld its improvement in progression-free and overall survival vs chemotherapy alone with longer follow-up of patients with advanced gastric, gastroesophageal junction, or esophageal cancer, according to data from the phase 3 CheckMate-649 trial.
Tisotumab vedotin elicited significant responses without prohibitive toxicity in combination with carboplatin as frontline therapy, as well as in combination with pembrolizumab as second- or third-line therapy in patients with recurrent or metastatic cervical cancer.
Adagrasib alone or in combination with cetuximab elicited encouraging antitumor activity and safety in heavily pretreated patients with KRAS G12C–mutant colorectal cancer, according to findings from the phase 1/2 KRYSTAL-1 trial.
When added to androgen-deprivation therapy, abiraterone acetate and prednisolone with or without enzalutamide for 2 years improved survival outcomes in men with high-risk nonmetastatic prostate cancer.
Hope S. Rugo, MD, discusses the overall survival data with first-line pembrolizumab plus chemotherapy as a treatment for patients with metastatic triple-negative breast cancer, as reported in the phase 3 KEYNOTE-355 trial.
Chan Cheah, MBBS, discusses the results of a study evaluating the efficacy and safety of TG-1701 alone and in combination with ublituximab and umbralisib in chronic lymphocytic leukemia.
Alexey V. Danilov, MD, PhD, discusses the efficacy of entospletinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.
Prednisone added to androgen-deprivation therapy plus docetaxel improved radiographic progression-free survival and overall survival in patients with de novo metastatic castration-sensitive prostate cancer.
Sabizabulin was well tolerated and associated with significant and durable objective tumor responses in patients with metastatic castration resistant prostate cancer.
A group of patients with metastatic castration resistant prostate cancer achieved favorable outcomes after receiving treatment with nivolumab in combination with rucaparib.
Switching maintenance to darolutamide following taxane-based therapy with at least 1 novel hormonal agent showed statistically significant but clinically modest improvement in radiographic progression-free survival and event-free survival in patents with metastatic castration-resistant prostate cancer.
The combination of ribociclib and letrozole demonstrated a statistically significant and clinically meaningful overall survival benefit compared with letrozole alone in the first-line setting for postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to results from the phase 3 MONALEESA-2 trial.
